It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
LiverMultiScan is an emerging diagnostic tool using multiparametric MRI to quantify liver disease. In a two-centre prospective validation study, 161 consecutive adult patients who had clinically-indicated liver biopsies underwent contemporaneous non-contrast multiparametric MRI at 3.0 tesla (proton density fat fraction (PDFF), T1 and T2* mapping), transient elastography (TE) and Enhanced Liver Fibrosis (ELF) test. Non-invasive liver tests were correlated with gold standard histothological measures. Reproducibility of LiverMultiScan was investigated in 22 healthy volunteers. Iron-corrected T1 (cT1), TE, and ELF demonstrated a positive correlation with hepatic collagen proportionate area (all p < 0·001). TE was superior to ELF and cT1 for predicting fibrosis stage. cT1 maintained good predictive accuracy for diagnosing significant fibrosis in cases with indeterminate ELF, but not for cases with indeterminate TE values. PDFF had high predictive accuracy for individual steatosis grades, with AUROCs ranging from 0.90–0.94. T2* mapping diagnosed iron accumulation with AUROC of 0.79 (95% CI: 0.67–0.92) and negative predictive value of 96%. LiverMultiScan showed excellent test/re-test reliability (coefficients of variation ranging from 1.4% to 2.8% for cT1). Overall failure rates for LiverMultiScan, ELF and TE were 4.3%, 1.9% and 15%, respectively. LiverMultiScan is an emerging point-of-care diagnostic tool that is comparable with the established non-invasive tests for assessment of liver fibrosis, whilst at the same time offering a superior technical success rate and contemporaneous measurement of liver steatosis and iron accumulation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 MRC/University of Edinburgh Centre for Inflammation Research, Queen’s Medical Research Institute, Edinburgh, UK
2 Centre for Liver Research and NIHR Birmingham BRC, University of Birmingham, Birmingham, UK; NIHR Nottingham BRC, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK
3 Institute of Translational Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
4 BHF/University of Edinburgh Centre for Cardiovascular Science, Queen’s Medical Research Institute, Edinburgh, UK
5 Imaging and Medical Physics, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
6 Perspectum Diagnostics Ltd., Oxford Centre for Innovation, Oxford, UK
7 MRC/University of Edinburgh Centre for Inflammation Research, Queen’s Medical Research Institute, Edinburgh, UK; Division of Pathology, Royal Infirmary of Edinburgh, Edinburgh, UK
8 Department of Cellular Pathology, Queen Elizabeth Hospital, Birmingham, UK
9 Centre for Liver Research and NIHR Birmingham BRC, University of Birmingham, Birmingham, UK; Department of Cellular Pathology, Queen Elizabeth Hospital, Birmingham, UK
10 Centre for Liver Research and NIHR Birmingham BRC, University of Birmingham, Birmingham, UK